Overview Statistic: PDF-Downloads (blue) and Frontdoor-Views (gray)

Effectiveness of Paxlovid - A Review

revision under review
  • Paxlovid is an oral treatment for mild to moderate COVID-19 cases with a high risk for severe course of the disease. For this review, we have performed a comprehensive literature review. We present a summary of currently available data on Paxlovid's ability to reduce the risk of progressing to a severe disease state. Our findings can be concluded as follows: data from the time when the Delta-variant was dominant shows that Paxlovid reduced the risk of hospitalization or death by 87.8\% for unvaccinated, non-hospitalized high-risk individuals. Data from the time when the Omicron variant was dominant found decreased risk reductions, varying between 41\% and 46\%, combining various vaccination statuses. However, one study, which differentiated by age, found that the administration of Paxlovid reduced the risk of hospitalization by 67\% for individuals aged 65 and older, but only by 27\% for individuals aged 40-64. From the available data, one can conclude that Paxlovid cannot substitute vaccination, but its low manufacturing cost as well as its easy administration make it a valuable tool in fighting COVID-19, especially for countries with a low vaccination rate.

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics - number of accesses to the document
Author:Sydney Paltra, Tim ConradORCiD
Document Type:Article
Parent Title (English):Frontiers in Public Health
Year of first publication:2023
Accept ✔
Diese Webseite verwendet technisch erforderliche Session-Cookies. Durch die weitere Nutzung der Webseite stimmen Sie diesem zu. Unsere Datenschutzerklärung finden Sie hier.